Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 162429 - 162429
Published: April 1, 2025
Language: Английский
Microorganisms, Journal Year: 2024, Volume and Issue: 12(2), P. 253 - 253
Published: Jan. 25, 2024
Antimicrobial resistance poses one of the greatest threats to global health and there is an urgent need for new therapeutic options. Phages are viruses that infect kill bacteria phage therapy could provide a valuable tool treatment multidrug-resistant infections. In this study, water samples collected by citizen scientists as part Citizen Phage Library (CPL) project, wastewater from Environment Agency yielded phages with activity against clinical strains Klebsiella pneumoniae BPRG1484 Enterobacter cloacae BPRG1482. A total 169 163 were found K. E. cloacae, respectively, within four days receiving strains. third strain (Escherichia coli BPRG1486) demonstrated cross-reactivity 42 already held in CPL collection. Seed lots prepared cocktail combining these was reduce melanisation Galleria mellonella infection model. The resources protocols utilised enabled rapid isolation characterisation targeted multiple future, clearly defined regulatory framework, be made available on named-patient basis UK.
Language: Английский
Citations
4
Clinical Microbiology Reviews, Journal Year: 2024, Volume and Issue: 37(3)
Published: July 29, 2024
SUMMARY Despite the early recognition of their therapeutic potential and current escalation multidrug-resistant (MDR) pathogens, adoption bacteriophages into mainstream clinical practice is hindered by unfamiliarity with basic pharmacokinetic (PK) pharmacodynamic (PD) properties, among others. Given self-replicative nature in presence host bacteria, adsorption rate, clearance host’s immunity, PK/PD characteristics cannot be estimated conventional approaches, thus, introduction new considerations required. Furthermore, multitude different bacteriophage types, preparations, treatment schedules impedes drawing general conclusions on vivo features. Additionally, drawback acquired resistance MDR pathogens environmental implications should taken consideration. Here, we provide an overview state field PK PD therapy a focus its application against Gram-negative infections, highlighting knowledge gaps challenges translation from bench to bedside. After reviewing vitro PKs PDs four major Klebsiella pneumoniae , Acinetobacter baumannii complex, Pseudomonas aeruginosa Escherichia coli specific data (tissue distribution, route administration, parameters animals humans) (survival reduction bacterial burden relation timing therapy, dosing regimens, resistance) are summarized. Currently available merit close scrutiny, optimization context better understanding underlying principles urgent improve effect minimize occurrence resistance.
Language: Английский
Citations
4
Essays in Biochemistry, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 10, 2024
Abstract Phage therapy has attracted attention again owing to the increasing number of drug-resistant bacteria. Although efficacy phage been reported, numerous studies have indicated that generation phage-specific antibodies resulting from administration might an impact on clinical outcomes. Phage-specific promote uptake by macrophages and contribute their rapid clearance body. In addition, neutralizing bind phages diminish antibacterial activity. Thus, antibody production its role in analyzed both vitro vivo. Strategies for prolonging blood circulation time also investigated. However, despite these efforts, results trials are still inconsistent, a consensus whether influence outcomes not yet reached. this review, we summarize during therapy. introduce recently performed discuss affect what can do further improve regimens.
Language: Английский
Citations
4
JCI Insight, Journal Year: 2024, Volume and Issue: 9(20)
Published: Oct. 22, 2024
With the increasing prevalence of antimicrobial-resistant bacterial infections, there is interest in using bacteriophages (phages) to treat such infections. However, factors that govern bacteriophage pharmacokinetics vivo remain poorly understood. Here, we have examined contribution neutrophils, most abundant phagocytes body, i.v. administered uninfected mice. A single dose LPS-5, a recently used human clinical trials drug-resistant Pseudomonas aeruginosa, was both immunocompetent BALB/c and neutropenic CD1 Phage concentrations were assessed peripheral blood spleen at 0.25, 1, 2, 4, 8, 12, 24 hours after administration by plaque assay qPCR. We observed phage clearance only minimally affected neutropenia. Indeed, half-lives phages mice 3.45 3.66 hours, respectively. These data suggest neutrophil-mediated phagocytosis not major determinant clearance. Conversely, substantial discrepancy circulating levels over time when measured qPCR versus assay, suggesting significant inactivation occurs time. indicate alternative factors, but inactivate phages.
Language: Английский
Citations
4
Molecular Therapy — Methods & Clinical Development, Journal Year: 2025, Volume and Issue: 33(1), P. 101410 - 101410
Published: Jan. 20, 2025
Accurate quantification of viral vectors and vaccines is a crucial step required before any downstream use virus preparations. The conventional immunocytochemistry-based method adenovirus has been widely used, but there are many areas for improvement toward accuracy resource consumption savings to reduce miscalculation wastage vaccination materials. In this work, one-step approach implemented optimized adenoviral that uses single antibody coupled with automated, high-throughput image acquisition subsequent batch analysis. First, cells infected the interest stained using Hexon protein. Then, multichannel automated via Invitrogen EVOS M7000 Imaging System performed. Last an large analysis acquired images Analysis Software, accomplished precise training software allowing infection additional parameters (counts, circularity, area intensity targets). It was found yielded accurate both oncolytic gene therapy in time- resource-effective manner when compared methodologies.
Language: Английский
Citations
0
Therapeutic Advances in Infectious Disease, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 1, 2025
Lower respiratory tract infections (LRTIs) pose a significant threat to global health, causing more than 2 million deaths worldwide. This menace is intensified by the alarming increase in drug resistance, which limits availability of effective antibiotics for bacterial infections. Consequently, there an urgent demand alternative therapeutic options. Phage therapy (PT) has re-emerged as promising approach and adjunct antibiotic treatment. systematic review synthesises application PT LRTIs humans, providing unified updated data on evaluation safety efficacy LRTIs. Systematic review. Following PRISMA guidelines, comprehensive search strategy was carried out (spanning January 2000 - February 2024) four databases: PubMed, Scopus, ScienceDirect Web Science retrieve published records humans only. The reference list each included study evaluated possible inclusion other relevant articles. Among 18 that fulfilled criteria, 70 patients were administered PT. Microbiologically, 71.42% (n = 50/70) improved; with either eradication pathogen or decrease load, whilst 15.71% 11/70) did not record any improvement. About 5.71% 4/70) recorded partial/incomplete improvement, 7.14% 5/70) microbiological outcomes unspecified. Clinically, up 74.29% 52/70) improved, 10.00% 7/70) showed no Another 2.86% 2/70) 12.86% 9/70) uncategorized. titres yielded positive ranged from 105 1012 PFU/mL. Studies achieved substantial phage titre at site infection frequently observed notable improvements. Regarding PT, 77.78% (N 14/18) studies adverse effects after administered, 16.66% 3/18) reported effects. Based recently originating mainly observational studies, shown considerable treatment However, lack uniform methodologies protocols across different cases management need additional clinical establish standardised pharmacokinetic elements overall protocol By doing so, we can fully unlock potential effectively managing infections, including
Language: Английский
Citations
0
PEDIATRICS, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 11, 2025
Bacteriophages are highly specific in targeting single pathogens the treatment of bacterial infections and thus offer a promising alternative to antibiotic therapies with potential for essentially no impact child’s own microbiome. have been evaluated by investigators several tissue site adults, but data children lacking. The application this therapy pediatrics provides an extraordinary opportunity redesign our approach directed, precision medicine antimicrobial infants both acute chronic infections, particularly those caused multidrug-resistant pathogens. In therapeutic approach, bacteriophage preparation would be selected exclusively limited patient’s pathogen, minimizing collateral damage microbiome, as often demonstrated therapy. following article, we describe these novel anti-infective biological agents, review recent literature, discuss practical considerations limitations, share applications topical systemic administration bacteriophages, either primary or combination traditional antibiotics. Additionally, important areas interest pediatric research discussed.
Language: Английский
Citations
0
Acta Biochimica Polonica, Journal Year: 2025, Volume and Issue: 72
Published: Feb. 11, 2025
Urinary tract infections (UTIs) are among the most common bacterial worldwide and increasing antimicrobial resistance (AMR) challenges conventional antibiotic treatments. Phage therapy (PT) has emerged as a promising alternative due to its specificity, safety efficacy against multidrug-resistant (MDR) pathogens causing infectious diseases. PT demonstrates significant potential in treating chronic recurrent UTIs, also including catheter-associated infection by reducing biofilms, delaying catheter blockage, enhancing when used combination. Clinical trials case studies have reported high rates of eradication symptom improvement with minimal side effects. Although endotoxin release immune activation during treatment should continue be investigated. The aim this review is present issues related use phages UTIs various etiological origins selected patients, those comorbidities, taking into account legal regulations, effectiveness experimental therapy. growing prevalence MDR uropathogens highlights urgent need for therapies, such based on order treat antibiotic-resistant improve patient outcomes. Despite great PT, clinical implementation routine requires rigorous trials, standardized production protocols regulatory advancements.
Language: Английский
Citations
0
Published: Jan. 1, 2025
Language: Английский
Citations
0
Advanced Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: March 3, 2025
Abstract The rise of antibiotic‐resistant bacteria, driven by antibiotic misuse, is a major global health threat. Addressing this issue requires understanding resistance mechanisms and developing innovative solutions. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)‐associated systems (Cas), genome‐editing tool derived from prokaryotic defense mechanisms, offers precise targeting genes. By reprogramming CRISPR‐Cas, bacteria can be killed or resensitized to antibiotics through plasmid curing. However, clinical applications face challenges, particularly in delivering CRISPR‐Cas components effectively. Nanotechnology has emerged as promising approach for targeted delivery tissues cells. This paper explores the molecular resistance, emphasizing structure function their mechanisms. It highlights use nanoparticles (NPs) nanoscale carriers deliver components, reviewing recent studies that combine NPs CRISPR target Additionally, discusses current challenges future prospects field, underscoring potential nanotechnology combat resistance.
Language: Английский
Citations
0